Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Our Pipeline


Our Pipeline

Amyndas is developing the next generation Compstatins, compounds targeting complement inhibition on cell surfaces by Compsorbin, and compounds targeting complement inhibition using factor H mini constructs. For more information, see technology.

Latest News

  • Το Βήμα: COVID-19 : Ελληνικό φάρμακο θα δοκιμαστεί σε βαριά ασθενείς στη χώρα μας

  • Το Βήμα: Κορωνοϊός: Ελληνικό φάρμακο για τους σοβαρά ασθενείς «νικά στα σημεία»

  • Quartesian Announces Amyndas Partnership for COVID-19 Clinical Trial

  • Το Βήμα: Ελληνικό φάρμακο ενάντια στην COVID-19

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2020 Amyndas Pharmaceuticals. All Rights Reserved.